1. Pink Sheet
  2. >>Market Access

Part D Copay Smoothing: Manufacturers Excluded From Financial Reconciliation Process

 
• By Cathy Kelly

Aiming for a threshold that ‘strikes the best balance,’ the final guidance from Medicare requires that plan sponsors and pharmacies use $600, single-prescription cost sharing at the point of sale to identify enrollees likely to benefit from the smoothing program and inform them about the option.

Part D Cost Sharing Can Be Spread Out Over The Year Beginning In 2025 • Source: Shutterstock (Shutterstock)

Manufacturers may not engage in the financial reconciliation process between Medicare Part D plans and beneficiaries as part of the cost sharing “smoothing” program established by the Inflation Reduction Act, according to final guidance by the Centers for Medicare and Medicaid Services.

Key Takeaways

  • Manufacturers can’t insert themselves in the reconciliation process between plans and beneficiaries, final guidance says.

The smoothing program is intended to make it easier for beneficiaries with very high-cost prescriptions to afford their co-pays by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 
• By Sarah Karlin-Smith

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

Clinical Trial Diversity Action Plan Guidance Must Return To US FDA Website, Court Says

 
• By Sue Sutter

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.

Industry Groups Back EU Life Sciences Strategy As Commission Pledges Clinical Trial Investment

 
• By Eliza Slawther

Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.